Project ALS is pleased to share that the FDA has approved the drug edaravone – the first approved ALS treatment in over 20 years.
Edaravone, a free radical scavenger, appears to react with nerve-damaging compounds generated as part of the disease process. After six months of treatment, on top of standard-of-care, data showed the intravenous drug reduced the rate of functional decline in patients by about a third.
Read more
A Statement From Lori Hermstad: On the Historic Results of the FUSION Trial for FUS-ALS.
Today, we hardly have words. After years of waiting, praying and hoping, the news we have dreamed of is finally here: the Phase 3 FUSION
September 25, 2026
No Comments
